http://www.biospace.comBioSpace RSS GeneratorSun, 26 May 2013 03:41:29 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.biospace.com/news_story.aspx?StoryID=297004&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><font size"3"><b>Roche and QB3 Team Up to Launch Successful Startups in the Bay Area </font></b><br><br>Basel, Switzerland and Seattle, WA, USA May 16, 2013 -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and the...Mon, 20 May 2013 12:00:00 AM GMThttp://www.bizjournals.com/sanfrancisco/blog/biotech/2013/05/bayer-qb3-mission-bay-capital-ucsf.htmlStaying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Bayer HealthCare has a matchmaker in QB3. Now it's formalizing that arrangement. The global drug giant announced Wednesday that it signed a three-year deal with the University of California institute and seed...Fri, 17 May 2013 12:00:00 AM GMThttp://www.xconomy.com/boston/2013/05/16/atlas-leans-on-amgen-novartis-to-build-new-crop-of-startups/Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br>Fresh off raising $265 million to bankroll its ninth fund, Atlas Venture has forged strategic partnerships with Amgen and Novartis to help supply the bigger companies with innovative new drug candidates. The...Thu, 16 May 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=294502&full=1Staying up-to-date has never been simpler. Sign up for the <a href"http://www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup">free GenePool newsletter</a> today!<br><br><div id"releaseBody"><p>SOUTH SAN FRANCISCO, CA--(Marketwired - April 25, 2013) - Theravance, Inc. (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTHRX">THRX</a>)<p><ul><li>Intention...Mon, 29 Apr 2013 12:00:00 AM GMThttp://www.bloomberg.com/news/2013-01-10/glaxo-says-no-plan-for-viiv-spinoff-at-the-moment-.htmlGlaxoSmithKline Plc (GSK) has no plans at the moment to spin off its ViiV Healthcare Ltd. unit that is developing drugs to treat HIV, said Patrick Vallance, Glaxos president of pharmaceuticals research and development. ViiV exists as a standalone company of which we are majority shareholders, he said in an interview in San Francisco, where he was attending JPMorgan Chase & Co.s health- care investment...Thu, 10 Jan 2013 12:00:00 AM GMThttp://www.xconomy.com/san-francisco/2013/01/09/prothena-of-south-san-francisco-gets-head-start-as-elan-spinoff/The whole is greater than the sum of its parts, goes the famous quote attributed to Aristotle. But biotechnology company Elan didnt see it that way when it split up its business units recently. In late December, Elan (NYSE: ELN) of Dublin, Ireland spun off its early stage drug discovery unit, now named Prothena, (NASDAQ: PRTA). Elan concluded that the two separated companies would each be worth...Wed, 09 Jan 2013 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=281280&full=1Vienna, 4 December 2012: APEIRON Biologics AG (Apeiron) today announced the launch of Attoquant Diagnostics GmbH (Attoquant) as a subsidiary. Attoquant will globally commercialize its already successfully marketed peptide analytics service RAS-FingerprintTM and further develop the underlying platform technology.</p><p>Vienna-based biotech company APEIRON Biologics AG (Apeiron) today announced the...Tue, 04 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=277827&full=1Integra Holdings closes U.S. $7.0 million private financing -<br><br>JERUSALEM--(BUSINESS WIRE)--Yissum Research and Development Company of the Hebrew University of Jerusalem, the technology transfer company of the Hebrew University, announced today the inception of its subsidiary, Integra Holdings, a holding company focusing on biopharmaceutical companies based on inventions of researchers from...Wed, 31 Oct 2012 12:00:00 AM GMThttp://invivoblog.blogspot.com/2012/10/say-what-inception-inks-hearing-loss.htmlInception Sciences, the discovery-stage biotech firm-slash-incubator created from the ground up to spin out assets in a buyer-friendly manner, has its first pharma partner. The San Diego firm has created a spin-off dubbed Inception 3 that will house a technology platform from Stanford University and develop drugs to treat permanent hearing loss. Roche is the partner, pledging R&D funds via undisclosed...Fri, 12 Oct 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=271900&full=1BRISBANE, 31 AUGUST 2012: Australian drug development company CBio Limited (ASX:CBZ) is pleased to advise that the merger with US based Inverseon Inc. has been successfully completed. </p><p>Dr William Garner has been appointed Managing Director and Chief Executive Officer of Invion Limited, and Dr Mitchell Glass has been appointed Executive Vice President of R&D and Chief Medical...Wed, 05 Sep 2012 12:00:00 AM GMThttp://www.thepharmaletter.com/file/115660/elan-to-spin-off-discovery-science-and-neotope-biosciences.htmlIreland's Elan (ELN.I) said on Monday it would spin off its Neotope drug discovery business platform as a separate public company in a move making Elan immediately profitable. The decision to split the company comes hard on the heels of the failure of an experimental Alzheimer's drug being developed with Pfizer (PFE.N) and Johnson & Johnson (JNJ.N), although Chief Executive Kelly Martin said it had...Tue, 14 Aug 2012 12:00:00 AM GMThttp://www.inpharm.com/news/173663/parkinson-s-specialist-spins-out-merck-serono-s-swiss-rd-opsGENEVA, July 30, 2012 /PRNewswire/ --</p><p>Prexton Therapeutics Will Develop Merck Serono's Metabotropic Glutamate Receptors Programs for Parkinson's Disease</p><p>Merck Serono, a division of Merck, Darmstadt, Germany, announced today the creation of Prexton Therapeutics, the first spin-off company resulting from its Entrepreneur Partnership Program launched in April 2012. Prexton Therapeutics...Mon, 30 Jul 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=256950&full=1<div class"xn-content"><p>BEERSE, <span class"xn-location">Belgium</span>, <span class"xn-chron">April 19, 2012</span> /PRNewswire/ --</p><p>Today sees the launch of Janssen Therapeutics EMEA, a division of Janssen Pharmaceutica NV, dedicated to bringing the investigational protease inhibitor TMC435 to hepatitis C patients in the EMEA region.</p><p>Approximately 130-210 million people are infected...Thu, 19 Apr 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=254388&full=1Tokyo, Japan, March 27, 2012 --- FUJIFILM Corporation (President and CEO Shigetaka Komori; hereinafter "Fujifilm") and Kyowa Hakko Kirin Co., Ltd. (President and CEO Nobuo Hanai; hereinafter "Kyowa Hakko Kirin") commenced business operations of the "FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd." (President and CEO Hideaki Nomura; hereinafter "Fujifilm Kyowa Kirin Biologics"), a joint-venture for the development...Tue, 27 Mar 2012 12:00:00 AM GMThttp://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20120319005624&newsLang=enGTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:<br><br>Vitrolife AB (publ)(STO:VITR) is today publishing the decision of the Board to begin preparations for a spin-off of the transplantation business, which today is run in the subsidiary Xvivo Perfusion AB. The spin-off will take place through distribution of the shares in the subsidiary in accordance with Lex Asea. It is intended that the...Mon, 19 Mar 2012 12:00:00 AM GMThttp://www.growingbusiness.co.uk/cardiff-university-medical-spin-out-asalus-secures-292-000.htmlCardiff-based medical instruments company Asalus has completed the first closing of a funding round set to reach almost 700,000 in two tranches. The deal, backed by regional fund Finance Wales and intellectual property commercialisation firms IP Group and Fusion IP, will facilitate the trial of a new device to clear the smoke arising from surgical procedures. The device, produced under the name Innervision...Wed, 29 Feb 2012 12:00:00 AM GMThttp://sciencecareers.sciencemag.org/career_magazine/previous_issues/articles/2012_02_24/caredit.a1200023A year ago, Pfizer announced a plan to exit its research and development site in Sandwich in southern England over the course of 2 years. At the time of the announcement, the site employed about 2400 workers. The company later announced that it would downsize the site instead of closing it. According to recent reports, 1500 employees will lose their jobs by the end of 2012 and 250 will be transferred...Fri, 24 Feb 2012 12:00:00 AM GMThttp://www.xconomy.com/boston/2012/01/10/warp-drive-bio-launches-with-125m-from-third-rock-greylock-sanofi/BOSTON & CAMBRIDGE, Mass., Jan 10, 2012 (BUSINESS WIRE) -- Third Rock Ventures and Warp Drive Bio today announced the launch of the new company and its broad strategic partnership with Sanofi /quotes/zigman/187275 FR:SAN 1.72% /quotes/zigman/307926/quotes/nls/sny SNY 1.23% , which positions the companies to transform the discovery and development of natural product drugs using Warp Drive Bio's proprietary...Tue, 10 Jan 2012 12:00:00 AM GMThttp://www.rttnews.com/1782109/covidien-to-spin-off-pharmaceuticals-business-update.aspx?type=bnDUBLIN--(BUSINESS WIRE)--Covidien plc (NYSE: COV), a leading global provider of healthcare products, today announced that it plans to spin off its pharmaceuticals business into a standalone public company. </p><p>Covidiens pharmaceuticals business is one of the worlds largest producers of bulk acetaminophen, the largest United States supplier of opioid pain medications and is among the top ...Thu, 15 Dec 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=237648&full=1HUDDINGE, Sweden--(BUSINESS WIRE)-- Regulatory News: Karo Bio AB (publ) is preparing a better allocation of resources and competences by spinning off the companys preclinical activities. This part will therefore be transferred into a subsidiary that is intended to become autonomous in operations as well as by ownership. The subsidiary will be proposed to assume the name Karo Bio. </p><p>Karo Bio...Tue, 25 Oct 2011 12:00:00 AM GMThttp://www.reuters.com/article/2011/09/12/britain-russia-pharmaceuticals-idUSL5E7KC0QA20110912<div class"xn-content"><p><span class"xn-location">MOSCOW</span> and <span class"xn-location">LONDON</span>, <span class"xn-chron">September 12, 2011</span> /PRNewswire/ --</p><p>- Anglo/Russian Venture Will Have Important Humanitarian Objectives From Day 1</p><p>Pro Bono Bio is a new international pharmaceutical company that launched today. Pro Bono Bio is the result of a three year Anglo/Russian...Mon, 12 Sep 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=231191&full=1STOCKHOLM--(BUSINESS WIRE)-- Allenex (STO:ALNX.st - News) transfers its holdings in the portfolio companies NovaHep AB and Recopharma AB to Alden Impact Capital AG, Zurich, who takes responsibility for the continued financing of their activities. </p><p>In NovaHep, focusing on liver stem cells, has Allenex been shareholder since 2005 and in Recopharma, with a focus on recombinant glyco proteins...Thu, 25 Aug 2011 12:00:00 AM GMThttp://www.cabume.co.uk/medtech/former-kudos-team-raise-p6m-from-p140m-imperial-fund.html25 August 2011 -- Imperial Innovations Group plc (AIM: IVO, Innovations, or the Group), the UKs leading technology commercialisation and investment company, has participated in a 6 million funding round into MISSION Therapeutics (MISSION), investing 1.3m. Sofinnova Partners led the round which also included SR One and Roche Venture Fund. Following the investment, Innovations will hold ...Thu, 25 Aug 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=223002&full=1PETAH-TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange, signed today an agreement to spin off its ophthalmic indications to a US based public company, Denali Concrete Management Inc. (OTC BB: DCMG.OB).</p><p>According...Mon, 06 Jun 2011 12:00:00 AM GMThttp://www.istockanalyst.com/business/news/5131171/aurobindo-pharma-net-up-13-plans-spin-offDrug maker Aurobindo Pharma is evaluating restructuring options including spinning off its active pharmaceutical ingredient and formulations unit in a bid to unlock value of an expanding segment of its business. The Hyderabad-based company made this announcement, and followed it with its results, which showed a net profit increase of 13% to 5.94 billion rupees ($132.94 million) for the year ended March...Tue, 10 May 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=219419&full=1May 04, 2011 -- Innate Pharma (Euronext Paris: FR0010331421) and Transgene (Paris:TNG) (Euronext Paris: FR0005175080) - two biotechnology companies specialized in the development of innovative immuno therapeutics, announce the creation of Platine Pharma Services ( Platine ). Platine is a new immunomonitoring1 company providing fee-based services to the healthcare industry for the preclinical and...Wed, 04 May 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=217624&full=1Amsterdam, The Netherlands, April 19, 2011 / B3C newswire / Avantium Pharma BV, a leader in solid state research and pre-formulation for the pharmaceutical industry over the last 11 years, has been spun out from Avantium Holding BV in a management buy-out to create Crystallics.</p><p>The new company will remain in Amsterdam, The Netherlands, and will specialize in solid state research and pre...Tue, 19 Apr 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=217071&full=1LONDON, UK, 13 April 2011 Plasticell Ltd, the biotechnology company developing high throughput stem cell technologies, has announced today that following its recent 3.5m financing, it has undergone a strategic re-structuring to enable the Company to focus on its award winning CombiCult technology for stem cell differentiation. Consequently, Plasticell Ltd has demerged its regenerative drug discovery...Wed, 13 Apr 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=208345&full=121 January 2011 -- A new company has been launched to commercialise an award-winning technology, developed at the University of Strathclyde in Glasgow, for tackling bacterial infection and contamination, including superbugs such as MRSA.</p><p>Fixed Phage Limited has been established to develop products based on its patented technology for treatment and prevention of infection and bacterial contamination...Fri, 21 Jan 2011 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=196856&full=1October 05, 2010 -- Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, announced today that it has completed the acquisition of Hypoxium Ltd to form the wholly-owned subsidiary Horizon Discovery Services Ltd (HDS). The newly formed contract research organization will provide oncology translational research services that include access...Tue, 05 Oct 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=195762&full=1Evreux, France, September 27, 2010 CIT, a leading European non-clinical CRO announced today the opening of its new U.S. subsidiary, CITox, Inc. The new company is based in Boston, Massachusetts, and will spearhead CITs planned expansion of its U.S. activities.</p><p>CIT simultaneously announced the appointment of Bernard Galat, 55, as Vice-President Business Development, North America. Galat...Mon, 27 Sep 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=192164&full=1Leuven (BELGIUM) August 25, 2010 - TiGenix (NYSE EURONEXT: TIG) has enteredinto an agreement with its academic partners, the Catholic University Leuven(KULeuven) and Ghent University (UGent), the Dutch company Therosteon and aconsortium of investors for the creation of a new small molecule drug developmentcompany, Arcarios, that will focus on the discovery and development of innovative,...Wed, 25 Aug 2010 12:00:00 AM GMThttp://www.qmed.com/news/22474/photocure-establishes-us-subsidiary-build-specialty-dermatology-businessQMED -- Photocure, a Norwegian pharmaceutical company specialising in dermatology and cancer, today announce the establishment of its US subsidiary, Photocure Inc, and the appointment of Terry Conrad as President to build its specialty dermatology business in the US.Wed, 04 Aug 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=187683&full=1Leiden, The Netherlands, July 19, 2010. Biotech company Pharming Group NV (Pharming) (NYSE Euronext: PHARM) today announces that, following the settlement agreement of May 2010 with the former DNage shareholders, which agreement initiated the spin-off of DNage, the spin-off has now become definitive. </p><p>In May 2010, Pharming announced the initiation of the spin-off of its wholly-owned subsidiairy...Mon, 19 Jul 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=181589&full=1SAN DIEGO & ZURICH & NEW YORK--(BUSINESS WIRE)--Phage Pharmaceuticals, Inc., a newly formed company, announced today that it and its parent company have acquired substantially all of the assets of Phage Biotechnology Corp., a debtor-in-possession in proceedings under Chapter 11 of the United States Bankruptcy Code. Coincident with this transaction, Phage Pharmaceuticals has received startup funding...Mon, 24 May 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=123582&full=1STOCKHOLM, SWEDEN--(MARKET WIRE)--Jan 22, 2009 -- Biovitrum AB (publ) (STO: BVT) today announced the initiation of a process aiming to spin out its small molecule UK based R&D subsidiary Cambridge Biotechnology (CBT) and a range of primary care projects. The proposed transaction reflects Biovitrum's previously announced decision to focus its in-house R&D on specialist pharmaceuticals and protein therapeutics...Thu, 22 Jan 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=111518&full=1Martinsried/Munich, October 1, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) and three private investors have founded Immunocore Ltd, which will focus on the technology platform for monoclonal T-cell receptors (mTCR) of MediGene's UK subsidiary MediGene Ltd. MediGene holds a 38.5% stake in Immunocore Ltd and will be the largest shareholder of the new company. </p><p> The further development...Wed, 01 Oct 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=104687&full=1Cologne (Germany), July 28, 2008 - DIREVO Biotech AG announced today the incorporation of a fully owned subsidiary named DIREVO Industrial Biotechnology GmbH. The new company was formed to spin-out DIREVO's industrial biotechnology business unit established at the beginning of 2007 and the recently acquired AC Biotec GmbH. The new company focuses on Food & Feed and Biorefinery markets and provides...Mon, 28 Jul 2008 12:00:00 AM GMThttp://in-pharmatechnologist.com/news/ng.asp?id=86307-progen-pharmasynth-pi-manufacturingBiotechnology firm ProGen Pharmaceuticals has spun-out its manufacturing operations as the new wholly-owned subsidiary PharmaSynth.Tue, 08 Jul 2008 12:00:00 AM GMThttp://www.reuters.com/article/marketsNews/idINT36292820080703?rpc=44TOKYO, July 3 (Reuters) - RaQualia, a pharma venture that was recently spun off by drug maker Pfizer Inc (PFE.N: Quote, Profile, Research, Stock Buzz), aims to go public by the first quarter of 2011, its president said on Thursday.Thu, 03 Jul 2008 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=98931&full=1Start-up could provide breakthrough treatment for vascular disease </p><p>PRINCETON, N.J.--(BUSINESS WIRE)--Battelle Ventures, LP, has spun out regenerative-medicine start-up NellOne Therapeutics, Inc. (NellOne), from the U.S. Department of Energys Oak Ridge National Laboratory (ORNL), with an initial $1.5-million seed investment from the fund and its Tennessee affiliate, Innovation Valley Partners...Wed, 04 Jun 2008 12:00:00 AM GMT